Cortechs.ai | Customer Spotlight: NeuroQuant – Changing Approach to Patients with Memory Loss

Customer Spotlight: NeuroQuant – Changing Approach to Patients with Memory Loss

Recently we had the privilege of speaking Sunil Ram, M.D., Neuroradiologist at Scottsdale Medical Imaging in Scottsdale, AZ about their 2014 decision to add NeuroQuant as an option in the evaluation of patients with memory loss.

Pursuing clinical excellence, advanced technology, innovation and research
For the past three decades, Scottsdale Medical Imaging (SMIL) has provided specialized, technology-driven imaging services and research in the greater Phoenix and Scottsdale areas. Their 35 sub-specialized radiologists and 14 state-of-the-art imaging centers make them a leading, majority physician-owned practice in the Southwest with patient care as their priority.

Cortechs.ai | Customer Spotlight: NeuroQuant – Changing Approach to Patients with Memory Loss

Traditional method of visual inspection had limitations
A 2013 study compared volumetric MRI imaging with NeuroQuant analysis in 20 patients with traumatic brain injury to a radiologist’s traditional method of visual inspection. They found that the NeuroQuant analysis identified 10 of 20 patients (50 percent) with atrophy compared to 2 of 20 (10 percent) identified by the radiologist’s traditional method of visual inspection.

Sunil Ram, MD, a Neuroradiologist at SMIL, says his group was already familiar with NeuroQuant’s reliability and established track record at respected academic medical centers around the country. SMIL’s decision to introduce NeuroQuant software to MRI brain imaging was because “the ability to quantify localized brain atrophy in minutes and compare to a large database of controls normalized for the patient’s age and gender allows us to apply that analysis in a routine clinical setting.”

Leading-edge technology, increased diagnostic accuracy, enhancing patient care
Advanced MRI neuroimaging coupled with automated volumetric data analysis now make it possible to identify any morphologic changes of the brain at the earliest onset of symptoms.

“Advantages of ordering a brain MRI with NeuroQuant analysis in a patient with memory loss can be twofold,” says Ram. “First, patients can be diagnosed sooner and more accurately.”

The second advantage is among patients suspected of having Alzheimer’s who have a normal NeuroQuant study result.

“Rather than pursuing a diagnosis of Alzheimer’s disease, clinicians can be directed to redouble their efforts to search for another potential source of memory loss.”

“The introduction of NeuroQuant has allowed us to provide a high level of care to our patients through consistent and accurate volumetric image analysis from MRIs. This in turn assists our area Neurologists and community providers to practice evidenced-based medicine with a data-driven approach,” Ram says.

Contact us to learn more about how NeuroQuant can help you improve brain image analysis, enhance the quality of patient care and use a data driven approach when evaluating memory loss and other neurological conditions.

 

Cortechs.ai | Customer Spotlight: NeuroQuant – Changing Approach to Patients with Memory Loss

More Resources

04/10/2026

OnQ Prostate Vendor Validation: From Research to Clinical Adoption

OnQ Prostate delivers consistent, reliable AI-powered prostate MRI insights across vendors, ensuring confident diagnosis and streamlined clinical workflows.

03/20/2026

Quantitative MRI, the McDonald Criteria, and the Future of Multiple Sclerosis Care

MRI is the foundation for diagnosing and monitoring multiple sclerosis (MS)

03/13/2026

Cortechs Cares: Community Impact and Volunteer Efforts in 2025

Cortechs Cares highlights how our team gave back in 2025 through community volunteer efforts, including an Alzheimer’s Walk and holiday toy drive.

03/11/2026

OnQ™ Prostate: Bringing Quantitative MRI to Prostate Imaging

Advancing prostate MRI with quantitative diffusion biomarkers. OnQ™ Prostate brings objective RSI-based insights to support data-driven cancer evaluation.

03/04/2026

Cortechs.ai and Siemens Healthineers Partner to Expand Global Access to NeuroQuant® Technologies

NeuroQuant® Lesion Surveillance will be integrated into the Siemens Healthineers Digital Marketplace to advance quantitative brain imaging worldwide.

02/25/2026

Cortechs.ai Announces MFDS (KFDA) Approval of Global-Leading NeuroQuant® V5 Platform in South Korea

MFDS approves NeuroQuant® V5 in South Korea, expanding AI-driven volumetric neuroimaging and clinical decision support.
Scroll to Top